ClinicalTrials.Veeva
Menu

Find clinical trials for Asthma in Madrid, MD

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Pulmonary Eosinophilia
Nasal Polyps
Rhinosinusitis
Allergic Rhinitis
Rhinitis
Sinusitis
Respiration Disorders

Asthma trials near Madrid, MD, ESP:

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. (ARRIVAL)

administration) to reduce maintenance therapy without loss of asthma control in adolescent and adults with severe asthma..Study det...

Enrolling
Severe Asthma
Combination Product: Budesonide/formoterol
Combination Product: Mannitol

Phase 3

AstraZeneca
AstraZeneca

Madrid, Spain and 83 other locations

in patients ≥ 6 to \< 18 years of age with severe eosinophilic asthma, including a well-documented history of asthma exacerbations ...

Enrolling
Asthma
Drug: Placebo
Drug: Benralizumab

Phase 3

AstraZeneca
AstraZeneca

Madrid, Spain and 83 other locations

The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will e...

Enrolling
Severe Asthma
Drug: Placebo
Drug: Verekitug (UPB-101)

Phase 2

Upstream Bio

Madrid, Spain and 122 other locations

To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled co...

Enrolling
Asthma
Biological: Tezepelumab
Other: Placebo

Phase 3

AstraZeneca
AstraZeneca

Madrid, Spain and 116 other locations

to budesonide in children from 6 to less than 12 years of age with asthma.* The study duration will be up to 37 weeks including an investiga...

Enrolling
Asthma
Drug: QMF149
Drug: Budesonide

Phase 3

Novartis
Novartis

Madrid, Spain and 51 other locations

BID using a dry-powder inhaler at one dose level over a 12-week Treatment period in adult participants with uncontrolled moderate-to-severe asthma...

Enrolling
Asthma
Drug: AZD4604
Other: Placebo

Phase 2

AstraZeneca
AstraZeneca

Madrid, Spain and 158 other locations

treatment in children 2 to \<6 years of age with uncontrolled asthma and/or recurrent severe asthmatic wheeze. The study will be conducted i...

Enrolling
Asthma
Wheezing
Drug: Placebo
Drug: Dupilumab

Phase 3

Sanofi
Sanofi

Madrid, Madrid, Comunidad De, Spain and 58 other locations

and safety with subcutaneous immunotherapy in patients with mild to moderate rhinitis / rhinoconjunctivitis with or without mild to moderate asthma...

Enrolling
Asthma, Allergic
Rhinoconjunctivitis
Other: Placebo
Biological: 30,000 MG01 + 10,000 T517

Phase 3

Inmunotek

Madrid, Spain and 25 other locations

and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma...

Enrolling
Asthma
Drug: Atuliflapon
Drug: Placebo

Phase 2

AstraZeneca
AstraZeneca

Madrid, Spain and 381 other locations

of clinically significant exacerbations in participants with severe asthma with an eosinophilic phenotype. Throughout the study, all partici...

Active, not recruiting
Asthma
Biological: GSK3511294 (Depemokimab)
Biological: Mepolizumab

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Madrid, Spain and 419 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems